Agoracom Blog

Enertopia Provides Media Update on Green Canvas Joint Venture

Posted by AGORACOM-JC at 8:04 AM on Tuesday, November 18th, 2014

Vancouver, BC / November 18 2014 / Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the “Company” or “Enertopia”) is very pleased to announce that Enertopia and The Green Canvas Ltd have jointly posted a four part video series on their respective websites. Green Canvas is currently in the process of applying to become a Licensed Producer pursuant to Canada’s new Marihuana for Medical Purposes Regulation (“MMPR”).

The 4 videos are about 5 min each and showcase why the use of Medical Cannabis is so important to so many people today. “No matter what city or town I have visited over the past year since entering the Medical Marijuana sector across Canada, the one recurring theme is the gratefulness from patients that Medical Cannabis has allowed many patients to regain some or most of their lives back from prescribed pain killers”, stated President CEO Robert McAllister

In a recent Globe and Mail article from October 3, 2014 it was reported that over 2,500 Canadian’s die each year from prescribed pain killers. Somewhere in Canada this year, a car accident claimed the life of someone who was taking eight different kinds of potent painkillers. We don’t know the person’s name, age, gender or even where the crash took place – just that he or she is one of the nearly 2,500 such death reports sent to Health Canada’s “adverse drug reaction” database.

Some who died took their own lives, while others had used the pills to get high. But many were people who had received a prescription from their doctor: a 49-year-old man with heart problems, a 51-year-old woman who overdosed, perhaps forgetting that her dosage had gone up, a 69-year-old man simply in “pain.” The entries are voluntary and imprecise (some deaths appear more than once), but the database is the closest the federal government comes to tracking the body count in the nation’s pitched battle with painkillers.

“For over ten years myself and The Green Canvas team have been working hard at trying to stop this madness with our ability to provide Medical Cannabis for patients in dire need of mental and physical pain relief”, stated Tim Selinski founder and President of The Green Canvas.

Robert McAllister, Enertopia Corporation., President & CEO said, “We are all witnessing today the emergence of the next great health and wellness industry of our times where the patient finally comes first.”

The youtube channel for the videos can be found at: http://www.youtube.com/user/EnertopiaCorp.

Further information on the Green Canvas can be found at www.thegreencanvas.ca/

The Company also announces the granting of 100,000 stock options at 10 cents per share for five years to a consultant to the Company.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning the appointment of The Green Canvas Ltd. and anticipated expertise of The Green Canvas or the MMPR application being granted by Health Canada having any positive impact on the Company, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Lexaria Updates Medical Marijuana and Cannabidiol Policies

Posted by AGORACOM-JC at 7:50 AM on Tuesday, November 18th, 2014

 

KELOWNA, BC / November 18, 2014 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces new medical marijuana and Cannabidiol (CBD) policies. Broadly speaking, subject to receiving a Canadian MMPR License, Lexaria does not plan to sell medical marijuana with THC content greater than 0.3% to persons under the age of 25, which brings our corporate policies in line with much of the medical community.

On August 28, Lexaria first announced its Responsible Marijuana Policy declaring Lexaria will not knowingly sell medical marijuana containing more than 0.3% THC to any medical marijuana patient who is under the age of 21.

That policy provoked more readership and commentary than any other action our company has taken in its history. This interest was not unexpected, however, since although selling to underage patients is permitted by the Health Canada MMPR, many health care practitioners are still reluctant to support the use of medical marijuana to treat underage patients.

Our underage policy made Lexaria CanPharm’s medical marijuana sales policies more restrictive than Canada’s alcohol consumption laws; and broadly in line with the USA’s alcohol consumption laws. We continue to believe it would not be responsible to provide medical marijuana with THC-psychoactive properties to underage persons whenever there is a CBD-based available alternative with medical properties that can meet a potential patient’s needs.

Subsequent to our policy statement, the College of Family Physicians of Canada created new guidelines that effectively included the recommendation that medical marijuana in most cases would not be appropriate for patients under the age of 25.

Accordingly, Lexaria is proud to announce that it is rising to a higher level of corporate responsibility so that, should it be granted a license with its joint-venture partner Enertopia Corp (ENRT) under the MMPR, it will follow the College of Family Physicians of Canada advice and will not knowingly sell medical marijuana containing more than 0.3% THC to any medical marijuana patient who is under the age of 25.

As part of its commitment to its customer’s health, Lexaria also will take all steps possible to encourage alternate methods of delivery that do not involve smoking. Together, this makes Lexaria’s policies the strongest announced by any corporation in North America.

Likewise, Lexaria will simultaneously be a strong supporter and advocate for the use of promising CBD-based therapies for patients of all ages, including under the age of 25.

Consider, the US Federal government, through the US Department of Health and Human Services, owns US Patent #6,630,507, which among other things, claims that

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”

It is in large part due to past research like this, that Lexaria is proud to be involved in the alternative health sector focused on the most efficient delivery of CBD’s to the human system possible.

For reference, cannabinoids are compounds that affect cannabinoid receptors located on many human cells. CB1 receptors are widely found within the human brain; and CB2 receptors are found with the human immune system and have been linked to anti-inflammatory and other responses.

Eighty-five different cannabinoids have been isolated from the cannabis plant, most of which do not have psychoactive properties. One that does have psychoactive properties is tetrahydrocannabinol (THC). Endocannabinoids are produced naturally in the human body while phytocannabinoids are produced in several plant species, most abundantly in the Cannabis plant.

Cannabidiol is one of the major phytocannabinoid forms of cannabinoids, contributing more than 35% of the extracts from the cannabis plant resin. Cannabidiol occurs naturally in other plant species beyond cannabis. For example the most widely acknowledged alternative source of phytocannabinoid is in the better understood Echinacea species, in widespread use as a dietary supplement. Most phytocannabinoids are virtually insoluble in water but are soluble in lipids and alcohol.

Cannabinoids can also be manufactured synthetically, although Lexaria has no plans to be involved in the synthetic cannabinoid industry.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana or alternative health businesses will provide any benefit to Lexaria. The Company makes no human health claims related to cannabinoids derived from any source.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Supreme Completes Private Placement for Aggregate Total of $1.78M

Posted by AGORACOM-JC at 7:49 PM on Monday, November 17th, 2014

VANCOUVER, BRITISH COLUMBIA–(Nov. 17, 2014) – NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

Supreme Pharmaceuticals Inc. (“Supreme” or the “Company“) (CSE:SL) is pleased to announce that it has closed the final tranche of its previously announced unit financing for gross proceeds of $815,893.44 (the “Financing“). At the final closing, Supreme issued 2,549,667 units (comprised of 2,549,667 common shares of the Company (“Common Shares“) and 1,274,834 Common Share purchase warrants (“Warrants“)) at a price of $0.32 per unit. Each Warrant is exercisable for one Common Share at a price of $0.50 per share prior to November 17, 2016, subject to an accelerated expiry period upon 30-days notice by the Company to the subscriber, if the Common Shares trade at or above $0.70 for any five (5) day period during the term of the Warrants. In aggregate, total gross proceeds raised from the first and second closings totalled $1,781,642.24 through the issuance of 5,567,632 Common Shares and 2,783,816 Warrants.

“Having raised almost double the proceeds that we initially sought when we announced our raise just three weeks ago, we’re pleased with the positive response we’ve had, and extremely gratified at the investment community’s ongoing interest in Supreme”, stated a director of the company. “With this raise now finalized, we have a strong balance sheet and are well-positioned to continue executing on our long-term growth strategy.”

The Company paid aggregate finder’s fees of $21,769.60 and issued 68,030 Warrants to certain arm’s-length parties in the connection with the subscriptions of certain subscribers who participated in the Financing.

The Common Shares and Warrants issued pursuant to the final tranche of the Financing are subject to a hold period that expires March 18, 2015. Following closing, Supreme has 76,031,197 Common Shares issued and outstanding.

The Company intends to use the aggregate proceeds of the Financing for the continuing development of the Company’s Kincardine facility and general working capital purposes.

FORWARD-LOOKING INFORMATION

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the use of proceeds of the Financing, as well as the Company’s corporate strategy. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan following the issuance of the required licenses by Health Canada. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
[email protected]
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

AGORACOM Small Cap TV “Best Of The Best” – November 17, 2014

Posted by AGORACOM-JC at 7:12 PM on Monday, November 17th, 2014

AGORACOM Founder, George Tsiolis and Chief Market Commentator, Allan Barry Go Via Satellite to discuss and debate Allan’s Best picks this week. Companies Included on this week’s show are:

WHY IS JULY 11, 2013 SO IMPORTANT?

Allan and George have already put their viewers well ahead of the game by starting their weekly broadcasts on July 11, 2013 on the thesis that great small-cap companies were so oversold they could not be ignored. One look at the TSX Venture Index proves they hit the nail on the head … but that doesn’t come close to telling the whole story with most of their picks far outperforming an index bloated with zombie companies.

Find out which companies Allan and George like this week by watching the video below!

Want to catch up on previous shows?

Weekly “Best Of The Best” Summarizing The Best Picks From Our Daily Shows. Posted Every Friday Afternoon Watch Here

THIS WEEK’S SHOW SPONSORED BY THE FOLLOWING GREAT SMALL CAP COMPANY:


Choosing Faith Over Fear. Not Religion. Faith

Posted by AGORACOM at 6:18 PM on Friday, November 14th, 2014
“I can tell you from experience, the affect you have on others is the most valuable currency there is; Because everything you gain in life will rot and fall apart and all that will be left of you, is what was in your heart” –Jim Carrey
“I don’t believe in hope.  Hope is a beggar”

Xylitol Canada Announces 60% Revenue Growth for the Nine Months Ended Sept 30, 2014

Posted by AGORACOM-JC at 4:49 PM on Friday, November 14th, 2014

TORONTO, ONTARIO–(Nov. 14, 2014) – Xylitol Canada Inc. (“Xylitol Canada“, or the “Company“) (TSX VENTURE:XYL) today announces that it has released its financial and operating results for the Fiscal 3rd Quarter and nine months ending September 30, 2014. Highlights of the results include:

“We are pleased that the commercial acceptance for our products continues to be at an all-time high as indicated by our 60% year over year revenue growth. The strong U.S. Dollar combined with geographic sales mix led to some margin compression during the quarter. Our product division intends to implement measures in Q4 to enhance gross margins as we enter our busiest season. We look forward to continued expansion of our product division as the negative pressure on refined sugar and artificial sweeteners continue to accelerate,” commented Andrew Reid, CEO of Xylitol Canada.

The Company also wishes to thank Frank Iadipaolo for his services as interim CFO during the 2nd and 3rd quarters of 2014. Mr. Iadipaolo was instrumental in setting up a robust internal control system, daily and weekly divisional reporting, and he architected an across the board costing and margin analysis program. Mr. Iadipaolo’s structural initiatives under a tight timeline are applauded. During this transition, the Company would like to welcome Kyle Appleby back to Xylitol Canada as CFO.

The full text of the Company’s interim consolidated financial statements and related management’s discussion and analysis (“MD&A”) can be found at: www.sedar.com.

About Xylitol Canada Inc.

Xylitol Canada markets xylitol and xylitol based-products and is focused on becoming a major low-cost manufacturer of xylitol and related products, serving the global market from operations in North America. Xylitol Canada’s business strategy is to leverage novel proprietary technology and processes to become North America’s premier manufacturer of low cost, high quality xylitol from readily available environmentally-sustainable biomass. Xylitol is a natural sweetener which is marketed globally including Canada and the United States and is accepted by the American Food and Drug Administration, the World Health Organization and the American Dental Association. Xylitol contains 75% less carbohydrates and 40% less calories than sugar, has a myriad of oral health benefits including the prevention of tooth decay and is safe for diabetics. To date, wider spread use of xylitol has been limited by the lack of a reliable, low cost, high quality supplier.

Neither TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

1-866-995-9952
[email protected]

KWG Files Amended and Restated Preliminary Short Form Prospectus for Equity Offering

Posted by AGORACOM-JC at 1:01 PM on Friday, November 14th, 2014

TORONTO, ONTARIO–(Nov. 14, 2014) – KWG Resources Inc. (“KWG” or the “Corporation“) (TSX VENTURE:KWG)(FRANKFURT:KW6) is pleased to announce that it has filed an amended and restated preliminary short form prospectus (the “Amended Prospectus“), which amends the preliminary short form prospectus filed by the Corporation on August 15, 2014. The Corporation has obtained a receipt from the securities regulatory authorities in the provinces of British Columbia, Ontario and Quebec in connection with a marketed offering (the “Offering“) of Units (as defined below) and Flow-Through Shares (as defined below) to be made in the provinces of British Columbia and Ontario. The Proposed Prospectus amends the proposed pricing of the Units, the proposed number of Units to be issued, the proposed pricing of the Flow-Through Shares and the number of Flow-Through Shares to be issued.

As previously disclosed in the Corporation’s press release dated August 18, 2014, the Corporation is targeting to raise minimum aggregate gross proceeds of $4 million (the “Minimum Offering“) and maximum aggregate gross proceeds of $10 million. The net proceeds of the Offering will be used to: (1) continue the development and commercialization of the new methods of production of chromium iron alloys from chromite ore and of production of low carbon chromium iron alloys (the “New Production Methods“); (2) conduct a drilling program at the Fishtrap Lake project; (3) continue the Corporation’s exploration program at the Koper Lake project; and (4) augment the Corporation’s working capital.

Secutor Capital Management Corporation (the “Agent“) has been appointed as exclusive lead agent for the Offering. The Corporation and the Agent have not yet entered into an agency agreement.

Each unit (a “Unit“) is comprised of three non “flow-through” common shares of KWG (each an “Offered Common Share“) and two non “flow-through” common share purchase warrants (each an “Offered Warrant“) at a price of $0.15 per Unit (the “Unit Offering Price“). Each Offered Warrant will entitle the holder to purchase one non “flow-through” common share of KWG (a “Warrant Share“) until the date that is 24 months following the closing of the Offering at a price of $0.10 per Warrant Share.

In addition, the Offering includes common shares of KWG, which will each qualify as a “flow-through share” (each, a “Flow-Through Share“) within the meaning of the Income Tax Act (Canada) at a price of $0.05 per Flow-Through Share (the “Flow-Through Offering Price“).

In connection with the Offering, the Corporation will grant to the Agent an option (the “Over-Allotment Option“) to sell, as agent, additional Flow-Through Shares (the “Additional Flow-Through Shares“), equal to not more than 15% of the number of Flow-Through Shares sold pursuant to the Maximum Offering, at the Flow-Through Offering Price and to purchase additional Units (the “Additional Units“), equal to not more than 15% of the number of Units sold pursuant to the Maximum Offering, at the Unit Offering Price to cover over-allotments, if any, and for market stabilization purposes. The Over-Allotment Option in respect of the Additional Flow-Through Shares will expire concurrently with the closing of the Offering. The Over-Allotment Option in respect of the Additional Units may be exercised at any time up to 30 days following the closing of the Offering.

Closing of the Offering is subject to certain conditions including, but not limited to, achievement of the Minimum Offering, the execution of a definitive agency agreement between the Corporation and the Agent and the receipt of all necessary approvals, including the approval of the applicable securities regulatory authorities and the TSX Venture Exchange.

The Amended Prospectus is still subject to completion or amendment. A copy of the Amended Prospectus will be available electronically at www.sedar.com. There will not be any sale of or any acceptance of an offer to buy the securities until a receipt for the (final) prospectus has been issued. The material set forth herein is for informational purposes only and does not constitute an offer of securities for sale in the United States or any other jurisdiction in which such an offer or solicitation is unlawful. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act“), or the laws of any state, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws. No public offering of securities will be made in the United States.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward‐Looking Statements: This Press Release contains or refers to “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. All information, other than information regarding historical fact that addresses activities, events or developments that KWG believes, expects or anticipates will or may occur in the future is forward-looking information. Forward-looking information contained in this Press Release is subject to a number of risks and uncertainties that may cause the actual results of KWG to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, KWG.
Should one or more of these risks and uncertainties occur, such as: the actual results of current exploration programs; risks normally incidental to exploration and development of mineral properties; the uncertainty of mineral resources estimates; uncertainties in the interpretation of drill results; the possibility that future exploration, development or mining results will not be consistent with expectations; the grade and recovery of ore varying from estimates; the general risks associated with the mining industry; the Corporation’s inability to maintain its title to its assets; the Corporation’s inability to obtain, maintain, renew and/or extend required licenses, permits, authorizations and/or approvals from the appropriate regulatory authorities and other risks relating to the applicable regulatory framework; environmental damages and the cost of compliance with environmental regulations; environmental risks; adverse land claims from First Nations groups or other parties; lack of adequate infrastructure; a lack of support from the Ontario government and federal government for the development of the Ring of Fire area; the patents to be used to support the commercialization of the New Production Methods will not be granted; capital and operating costs varying significantly from estimates; slowing demand for ferrochrome products; adverse general market conditions; inflation; changes in exchange and interest rates; adverse changes in commodity prices; the impact of consolidation and rationalization in the steel industry; competition; risk that amendments to current laws, regulations and permits governing operations and activities of mining companies will have a material adverse impact the Corporation; the risk that the New Production Methods does not prove efficient or economical; intellectual property litigation; risks related to the tax treatment of the Flow-Through Shares; and, management’s discretion as to use of proceeds, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. KWG does not intend and do not assume any obligation to update these forward
‐ looking statements, except as required by law. Readers are cautioned not to put undue reliance on such forward‐looking statements.

Shares issued and outstanding: 777,842,468

KWG Resources Inc.
Bruce Hodgman
Vice-President
416-642-3575
[email protected]

Secutor Capital Management Corporation
Arie Papernick
(416) 847-1220

Neah Power Systems – Q&A Session Vol. 5 – November 13, 2014

Posted by AGORACOM-JC at 4:13 PM on Thursday, November 13th, 2014
Welcome to AGORACOM Q&A. We have invited Neah Power Systems Investors to ask questions which have been answered directly by management.With us today is Dr. Chris D’Couto President of Neah Power Systems, a developer of fuel cell power solutions using proprietary, award winning technology for the military, transportation, and portable electronic devices.

$50M+ Invested into Neah Power Systems

  • Intel Corporation, Novellus Systems, Four Tier 1 VCs, US Navy, NIST/ATP
  • award winning technology (Popular Science, MIT)

Hub On AGORACOM / Corporate Website / Watch Interview Now!
 

Health & Wellness Business Plan by Lexaria

Posted by AGORACOM-JC at 8:10 AM on Thursday, November 13th, 2014

 

KELOWNA, BC / November 13, 2014 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”).

Lexaria is in the midst of a major corporate transformation that began with our announcement on March 5, 2014, when we made a strategic entry into the Canadian medical marijuana sector. Since then we have added staff and consultants with expert knowledge of the sector, and our first licence submission to grow and sell medical marijuana in Canada is working its way through the Health Canada license application process.

Lexaria is increasingly focusing our valuable management time on a single corporate target: Lexaria wants to help people feel as healthy as they can. Our application to grow and sell marijuana under the MMPR regulations in Canada is part of that strategy; the PoViva Tea acquisition announced yesterday is another part of that same strategy; and additional planks in this strategy will be announced very soon.

While continuing to work towards LP (Licensed Producer) status in Canada, Lexaria believes firmly that our shareholders should not have to wait an indeterminate amount of time for clarity through the government licensing process. Instead, with PoViva Teas and other pending product announcements which we expect to be forthcoming shortly, Lexaria has aggressively entered the already legal CBD-enhanced marketplace.

Lexaria is examining opportunities in some of the most popular beverage and food categories in the USA and in the world.

The Alternative Health sector is large and growing. A long term Medical Expenditure Panel Survey was conducted from 2002 until 2008 with at least 29,370 subjects asked repeatedly if they had seen any kind of health care practitioner in the previous six months. The survey recorded whether the health care provider was a “complementary and alternative medicine care professional,” including “homeopathic, naturopathic, or herbalist.”

Between 5.3% and 5.8% of the survey group at any one time reported that they had seen a complementary or alternative medicine provider. Based on the US population of ~319,000,000, this suggests between 16.9 million and 18.5 million Americans are seeking an alternative health care professional at any given time.

Meanwhile the Centers for Disease Control and Prevention, in an April 2011 NCHS Data Brief, reported that more than 50% of the population uses dietary supplements of one kind or another. Detailed findings from that report included:

– Use of dietary supplements is common among the U.S. adult population. Over 40% used supplements in 1988–1994, and over one-half in 2003–2006.

– Multivitamins/multiminerals are the most commonly used dietary supplements, with approximately 40% of men and women reporting use during 2003–2006.

– Use of supplemental calcium increased from 28% during 1988–1994 to 61% during 2003–2006 among women aged 60 and over.

As we previously reported, more than 150 million Americans drink tea every day, amounting to some 79 billion servings of tea in America every year. Our launch of Poviva Tea Corp is meant to tap into this strong existing demand. PoViva has filed two patents pending to bind active CBD ingredients with a lipid, allowing for more efficient and comforting delivery of the CBD.

The legal medical marijuana market, in comparison, is much smaller measure both by number of patients as well as by total dollar volume.

Our goal is to begin producing cash flows from these initiatives as soon as possible; focused on the immediate opportunities in the CBD-sectors derived from already-legal hemp. CBD’s (Cannabidoil) have been found by many researchers to have antioxidant properties and Lexaria plans to use the patent pending process it has acquired with PoViva teas, to infuse CBD’s into a number of popular food and beverages.

Lexaria is planning to launch a line of premium products, always relying on our patent pending CBD-infusion process, to bring CBD’s into the mainstream. Because CBD’s do not have psychoactive properties we expect our products to appeal to the widest possible customer base. Initially we will focus our sales efforts across the continental USA.

Lexaria has commissioned a new website which is currently under development. When the site is in operation, customers will be able to place orders and interact with normal e-commerce capabilities. A national distribution center is also being contracted to ensure rapid and accurate fulfillment of all orders. A 1-800 ordering center will also be placed into operation.

Early in 2015 Lexaria will begin working on traditional retail sales channels and will work to continually develop those “bricks and mortar” sales methods. Also early in 2015 we hope to add our next CBD-based product line.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana or alternative health businesses will provide any benefit to Lexaria. There is no assurance that PoViva Teas will be accepted into the marketplace or have any positive impact upon Lexaria Corp. There is no assurance that PoViva Teas will promote, assist, or maintain any beneficial human health conditions whatsoever.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Stria Lithium Announces Funding Commitment from the Government of Canada

Posted by AGORACOM-JC at 10:17 AM on Wednesday, November 12th, 2014

 

Innovation Funding Commitment to assist in the Company’s Development of Novel, Environmentally Sustainable Lithium Processing Technologies

 

OTTAWA, ONTARIO–(Nov. 12, 2014) – Stria Lithium Inc. (TSX VENTURE:SRA) (“Stria” or the “Company”) is pleased to announce that it has received a funding commitment of up to $137,700 from the Government of Canada through the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) in support of the Company’s continuing development of novel lithium processing technologies aimed at producing low-cost, very high purity lithium products.

Stria Lithium is advancing development of proprietary spodumene mineralization to lithium concentrate processing technologies capable of producing a low cost high-grade Li-metal, Li-carbonate and Li-hydroxide products.

On October 17, 2014, the Company announced it had completed a dense media separation study (“DMS”) with SGS Canada Ltd., demonstrating the mineralogical quality and viability for purification of spodumene mineralization from its 100% owned Pontax Lithium Project, Northern Quebec.

The mineralization will be used to feed Stria’s pilot plant located in Kingston, Ontario, scheduled for startup in early 2015.

Stria President and Chief Operating Officer Julien Davy said: “The federal government’s commitment of financial support bodes well for us in meeting our planned future production milestones, beginning with our pilot plant in Kingston. We are extremely grateful for NRC-IRAP’s business and technical advisory services, along with financial support, at this time in our process development.”

“Battery manufacturers are looking to the resource sector to find innovative solutions to lower production costs.

“Our decision to build our business on the development of new, proprietary processing technologies has attracted industry attention,” Mr. Davy added. “We believe our technologies hold the prospect of resolving not only cost and purity issues, but also, an industry imperative to do so on an environmentally sustainable basis.”

Stria’s aim is to license its potential technologies to electric vehicle and large-scale industrial energy storage battery manufacturers.

“Being able to ‘walk the talk,’ environmentally speaking,” Mr. Davy said, “is critical to our future success in the lithium industry.”

About Stria Lithium Inc.

Stria Lithium (TSX VENTURE:SRA) is a Mining Technology company that owns the Pontax spodumene lithium property in Northern Quebec and the Willcox brine lithium property in southeastern Arizona. As announced in January 2014, Stria is developing proprietary, in-house processing technologies for both projects with the purpose of reducing processing costs on an environmentally sustainable basis.

Stria’s technologies, based on recovering lithium metal directly from mineralization and from brine liquids, will be more efficient, will require fewer controls, less chemistry and require less energy from compact facilities designed to enable easy automation.

Forward Looking Statement – Disclaimer

This news release may contain forward-looking statements, being statements which are not historical facts, and discussions of future plans and objectives. There can be no assurance that such statements will prove accurate. Such statements are necessarily based upon a number of estimates and assumptions that are subject to numerous risks and uncertainties that could cause actual results and future events to differ materially from those anticipated or projected. Important factors that could cause actual results to differ materially from the Company’s expectations are in our documents filed from time to time with the TSX Venture Exchange and provincial securities regulators, most of which are available at www.sedar.com.

Stria Lithium Inc.
Mr. Julien Davy
President and COO
[email protected]